In conclusion, our results do not suggest a major role for the CYP17 promoter polymorphism in breast cancer risk in general among males or females, but we were not able to exclude an association with breast cancer risk in male BRCA2 carriers because of the small sample size. Here, CYP17A1 is linked to breast carcinoma.